Genomic Landscapes and Targeted Therapies in Leukemia
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 December 2026 | Viewed by 75
Editor
Interests: gastric cancer; leukemia; molecular biomarkers; genotoxicity; pharmacology; precision oncology and genomic characterization
Special Issue Information
Dear Colleagues,
Leukemia encompasses a highly heterogeneous group of hematological malignancies driven by complex genetic and epigenetic alterations. Over the past decade, advancements in precision oncology and genomic characterization, particularly through next-generation sequencing (NGS), have revolutionized our understanding of the underlying biology of these diseases. Unraveling the genomic landscape of various leukemias—such as acute myeloid leukemia (AML) and lymphoid leukemias—has been pivotal in identifying novel molecular biomarkers. These discoveries are essential for shifting the treatment paradigm from broad cytotoxic chemotherapy towards highly specific targeted therapies, ultimately improving prognostic accuracy, mitigating genotoxicity, and enhancing patient survival.
We are pleased to invite you to contribute to this Special Issue, which will showcase a robust collection of high-quality research bridging the gap between basic genomic science and clinical pharmacology in the context of leukemia. By focusing on molecular biomarkers, therapeutic targets, and precision oncology, this Special Issue will directly support the mission of Biomedicines to advance translational research and therapeutic innovation from bench to bedside.
For this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Genomic and transcriptomic characterization of leukemias (e.g., acute myeloid leukemia, chronic lymphocytic leukemia);
- Identification and clinical validation of novel molecular biomarkers for diagnosis, prognosis, and therapeutic response;
- Development, efficacy, and pharmacology of targeted therapies in leukemia;
- Mechanisms of drug resistance and genotoxicity in hematopoietic malignancies;
- Application of advanced molecular biology techniques (such as CRISPR-Cas9, NGS, and qPCR) in modeling leukemia or identifying genetic vulnerabilities;
- The role of precision oncology in personalizing patient care and improving clinical outcomes.
I look forward to receiving your contributions.
Prof. Dr. André S. Khayat
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- leukemia
- precision oncology
- genomic characterization
- targeted therapy
- molecular biomarkers
- acute myeloid leukemia
- pharmacogenomics
- next-generation sequencing
- CRISPR-Cas9
- hematological malignancies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
